Lifestyle
- regular physical activity
- stress management
- adequate sleep
Blutsenkungsgeschwindigkeit · ESR · Erythrozyten-Sedimentationsrate · Erythrocyte Sedimentation Rate
ESR quantifies the rate at which erythrocytes settle at the bottom of a test tube over one hour, indicating the presence of inflammation.
Reference ranges can vary by age and sex; women and older adults may have slightly higher values.
The erythrocyte sedimentation rate (ESR), also known as Blutsenkungsgeschwindigkeit (BSG) or Erythrozyten-Sedimentationsrate, is a blood test that measures the rate at which red blood cells sediment in a period of one hour. It is a non-specific marker of inflammation, reflecting the presence of acute phase reactants in the blood, which cause red blood cells to clump together and settle more quickly. Clinically, ESR is used to detect inflammation associated with conditions such as infections, cancers, and autoimmune diseases. It is often used in conjunction with other tests, like C-reactive protein (CRP), to provide a more comprehensive view of inflammatory activity. In the context of athletic performance, biohacking, or longevity, ESR may be monitored to assess systemic inflammation, which can impact recovery, performance, and overall health. However, its non-specific nature means it should be interpreted cautiously and in conjunction with other markers. Several factors can confound ESR results, including age, sex, pregnancy, anemia, and certain medications. Additionally, variations in testing methods, such as the Westergren method or its modifications, can affect results. Therefore, consistent methodology and consideration of individual patient factors are crucial for accurate interpretation.
Klinische Bedeutung
Elevated ESR values typically indicate the presence of inflammation due to conditions like infections, autoimmune diseases, or malignancies. Low ESR values are less common and may not be clinically significant.
Progressively rising ESR values suggest worsening inflammation or disease activity. Re-test in 4-6 weeks if clinically indicated.
Progressively falling ESR values suggest resolution of inflammation or effective treatment.
Re-test Interval
4-6 weeks if outside optimal range
Note:
Consult a healthcare provider before starting any new supplement regimen.
Testing Frequency
As needed based on clinical indications.
Correlated with
Current research suggests that discrepancies between ESR and CRP measurements, particularly in chronic inflammatory diseases, remain understudied, with no consensus on reference ranges or optimal targets. Researchers have not yet established standardized methodologies for ESR testing, leading to variability in results across different techniques. Additionally, clinical questions regarding the specific conditions under which ESR and CRP discordance occurs and its implications for patient management remain unanswered.
1,070
Total Citations
25
Human/RCT
5.3
Avg. Influence
2025
Latest
Bray Christopher, et al. · WMJ : official publication of the State Medical Society of Wisconsin · 2016
This review examined the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) as markers of systemic inflammation. Researchers found that both markers lack sensitivity and specificity, and discrepancies between their measurements are common, particularly in chronic inflammatory diseases. Proper utilization of ESR and CRP continues to play an important role in clinical management.
Key findings
This review focused on biomarkers for inflammatory bowel disease (IBD), highlighting the challenges in diagnosis and monitoring. Researchers found that current biomarkers like CRP and ESR are not ideal, and ongoing studies aim to identify better options. The review summarized recent advances in IBD biomarkers.
Inciarte-Mundo José, et al. · Frontiers in immunology · 2022
This study focused on calprotectin (S100A8/S100A9) as a biomarker in rheumatoid arthritis (RA). Researchers found that higher calprotectin levels correlate better with disease activity than CRP or ESR. Additionally, calprotectin levels decreased after treatment, indicating its potential as a biomarker for monitoring RA.
Key findings
This research focused on modified and alternate methods for measuring the erythrocyte sedimentation rate (ESR). Researchers found that only 28% of laboratories used the traditional Westergren method, with new methods showing significant differences in results. Recommendations for validating these new methods were developed by a panel of experts.
This study proposed circulating microRNA223 as a new biomarker for inflammatory bowel disease (IBD). Researchers found that serum miR-223 levels were significantly elevated in IBD patients compared to healthy controls and correlated with disease activity indicators. This suggests miR-223 may be a promising noninvasive monitoring tool.
This review explored the interaction between cyclophilin A and CD147 in cancer. Researchers observed a significant association between the overexpression of genes encoding these proteins and poor prognosis in various tumors, suggesting their potential as therapeutic targets.
This study investigated the adsorption behavior of uranium (U(VI)) on granite, not directly related to blood biomarkers. Researchers found that pH and counter ions significantly affect U(VI) adsorption. The findings contribute to understanding environmental interactions rather than clinical biomarkers.
This study aimed to reduce inappropriate ordering of erythrocyte sedimentation rate (ESR) tests in a clinical setting. Researchers found that implementing computerized clinical decision support led to a 40% reduction in ESR orders. The findings suggest that provider habits contribute to overutilization of ESR testing.
This study reevaluated normal values for the erythrocyte sedimentation rate (ESR) across a wide age range. Researchers found that upper limits of normal ESR values were slightly above standard laboratory values, with an age-related increase noted, particularly in women and men in their 50s.
This review highlighted the importance of biomarkers in rheumatoid arthritis for diagnosis and management. Researchers noted ongoing investigations into both established and potential new biomarkers to improve clinical outcomes for RA patients.
Research publications about BSG over time
9totalLog lab results, track trends and optimize your biomarkers over time.
This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer